To explore the role of the glucagon-like peptide 1 receptor (GLP-1R) in geniposide regulated insulin secretion in rat INS-1 insulinoma cells. Rat INS-1 insulinoma cells were cultured. The content ...

司美格鲁肽 是一种胰高血糖素样肽-1 受体（GLP-1）激动剂，它彻底改变了 2 型糖尿病的治疗方式， 近年来还被广泛用于治疗肥胖症，成为减肥和降低心血管疾病风险的良方。

GLP-1 Agonist Peptides against Type 2 Diabetes Are Promising Targets for Patients with Poor Hb1Ac Control Type 2 diabetes is a major risk factor for cardiovascular disease related morbidity and ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

UK health authorities are investigating pancreatitis cases linked to weight-loss drugs like Ozempic and Mounjaro. We spoke to ...

As a result, the mechanisms underlying the impact of glucagon-like peptide-1 medications on the kidneys are unknown. Clinical trials and animal research support GLP-1 medication usage to treat ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

In 2021, the global glucagon-like peptide 1 (GLP-1) market was valued at US$16.53 billion, and is probable to reach US$24.10 billion by 2027. The glucagon-like peptide 1 (GLP-1) market is ...

Novel Glucagon like peptide-1 (GLP-1) drugs designed for type II diabetes. Hefei Institutes of Physical Science, Chinese Academy of Sciences . Journal Pharmaceuticals DOI 10.3390/ph15060740.